Livoletide

DB15188InvestigationalSmall molecule

Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).

Chemical structure of Livoletide
Formula / weight
C40H63N15O13 · 962.036 g/mol (avg)
Code names
AZP-531

Resolves to

Compound
UNII9VHD7J6363CAS1088543-62-7ChEMBLCHEMBL2029605
Structure
InChIKeyJXPWLIYXIWGWSA-CLBRJLNISA-NSMILES[H][C@@]12CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(O)=O)NC2=O)C(C)C
Targets
Q92847GHSR

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Livoletide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In